Tags

Type your tag names separated by a space and hit enter

Obesity Pharmacotherapy.
Med Clin North Am. 2018 Jan; 102(1):135-148.MC

Abstract

Although diet, physical activity, and behavioral modifications are the cornerstones of weight management, weight loss achieved by lifestyle modifications alone is often limited and difficult to maintain. Pharmacotherapy for obesity can be considered if patients have a body mass index (BMI) of 30 kg/m2 or greater or BMI of 27 kg/m2 or greater with weight-related comorbidities. The 6 most commonly used antiobesity medications are phentermine, orlistat, phentermine/topiramate extended release, lorcaserin, naltrexone sustained release (SR)/bupropion SR, and liraglutide 3.0 mg. Successful pharmacotherapy for obesity depends on tailoring treatment to patients' behaviors and comorbidities and monitoring of efficacy, safety, and tolerability.

Authors+Show Affiliations

Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA. Electronic address: kph2001@med.cornell.edu.Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA.Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA.Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA.Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29156182

Citation

Saunders, Katherine H., et al. "Obesity Pharmacotherapy." The Medical Clinics of North America, vol. 102, no. 1, 2018, pp. 135-148.
Saunders KH, Umashanker D, Igel LI, et al. Obesity Pharmacotherapy. Med Clin North Am. 2018;102(1):135-148.
Saunders, K. H., Umashanker, D., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2018). Obesity Pharmacotherapy. The Medical Clinics of North America, 102(1), 135-148. https://doi.org/10.1016/j.mcna.2017.08.010
Saunders KH, et al. Obesity Pharmacotherapy. Med Clin North Am. 2018;102(1):135-148. PubMed PMID: 29156182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Obesity Pharmacotherapy. AU - Saunders,Katherine H, AU - Umashanker,Devika, AU - Igel,Leon I, AU - Kumar,Rekha B, AU - Aronne,Louis J, PY - 2017/11/21/entrez PY - 2017/11/21/pubmed PY - 2017/12/13/medline KW - Liraglutide KW - Lorcaserin KW - Naltrexone/bupropion KW - Obesity KW - Orlistat KW - Pharmacotherapy KW - Phentermine/topiramate KW - Weight management SP - 135 EP - 148 JF - The Medical clinics of North America JO - Med. Clin. North Am. VL - 102 IS - 1 N2 - Although diet, physical activity, and behavioral modifications are the cornerstones of weight management, weight loss achieved by lifestyle modifications alone is often limited and difficult to maintain. Pharmacotherapy for obesity can be considered if patients have a body mass index (BMI) of 30 kg/m2 or greater or BMI of 27 kg/m2 or greater with weight-related comorbidities. The 6 most commonly used antiobesity medications are phentermine, orlistat, phentermine/topiramate extended release, lorcaserin, naltrexone sustained release (SR)/bupropion SR, and liraglutide 3.0 mg. Successful pharmacotherapy for obesity depends on tailoring treatment to patients' behaviors and comorbidities and monitoring of efficacy, safety, and tolerability. SN - 1557-9859 UR - https://www.unboundmedicine.com/medline/citation/29156182/Obesity_Pharmacotherapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0025-7125(17)30134-7 DB - PRIME DP - Unbound Medicine ER -